Anonymous
I gained more awareness and knowledge about requirements to move from the pre-clinical to the clinical setting. I was very satisfied with the course content and the high expertise of the presenters.
Anonymous
I have gotten much more knowledge about the legal aspects of NDAs and CTAs and now know better how to critically view their content. The trainer was very communicative and open to questions, with really good and insightful answers.
Mieke Tempels
Being able to set up and manage Risk Management for clinical studies. Well organised, good trainers. I did appreciate this blended approach in learning.
Josefien Dedoncker
I had an overall (all-inclusive) overview of CPM + tips and tricks for on the job (cf. annexes, documents, workshops). I liked the positive engagement with and the classroom's motivation, of the teacher and co-attendants.
Elisabeth Cobraiville
Good refresh and good tips on conducting medical devices clinical trials. Very interactive training with the opportunity to share experiences between trainees and trainers.
Michael Papadimitrious
The trainer was very well able to stimulate the course participants to engage in this refresher training course. Most of my colleagues have now taken this course - however for the ones that have not taken the course I would happily recommend it!
Anonymous
For me, it was a double benefit. As I represent CRO, from one site it was good to learn Sponsor criteria how they evaluate the CROs, what are the oversight requirements as the same I would need to implement when as CRO selecting our Partners and Vendors. Interactive discussion, exchanges with experience from the Trainer and
Benoit de Malglaive
With this course, I learned more about risk identification which leads to a decrease of quality and became more prepared for when I do an audit.
Anonymous
I've received the proper knowledge on the main CRO management aspects and useful information to further develop my management skills.
Jodie van der Kuilen
I gained more insights and knowledge about the clinical project management oversight instead of one part of the clinical trial. Very well structured and a good way of learning new things!